A new, large-scale study has found adding an electrocardiogram (ECG) to the latest generation of body-worn sensors accurately detects atrial fibrillation (AF) and significantly increases awareness of heart rate and behavior. Body-worn or wearable wireless sensors are increasingly being used to help collect health-related information that can be shared with a doctor through a smartphone application. The study results show that by using ECG sensors with a smartphone application, the general adult population can efficiently track their heart rate data. The new findings were presented at Heart Rhythm 2015, the Heart Rhythm Society’s 36th annual scientific sessions.



A new expert consensus statement by the Heart Rhythm Society (HRS) recommends remote monitoring (RM) become standard of care for patients with cardiovascular implantable electronic devices (CIEDs). The HRS Expert Consensus Statement on Remote Interrogation and Monitoring for Cardiovascular Electronic Implantable Devices was written by an international group of experts and published online in HeartRhythm Journal, the official journal of HRS. This new approach presents a new paradigm for managing patients with CIEDs and will be presented at Heart Rhythm 2015, the Heart Rhythm Society’s 36th Annual Scientific Sessions.



Prasugrel (Effient) is more likely to be given to lower-risk heart disease patients undergoing percutaneous coronary intervention (PCI) compared to clopidogrel, according to a new study. Results of the PROMETHEUS study, which examined how the two drugs are used across academic medical centers in the United States, were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2015 Scientific Sessions in San Diego.


Geneva Healthcare will showcase a set of new features on The Geneva Healthcare Suite – a technology platform for managing data from cardiac devices – at Heart Rhythm Society's annual scientific sessions in Boston. The cloud-based software suite organizes device data from multiple sources on an intuitive dashboard to provide critical health information to clinicians in real time. New features in The Geneva Healthcare Suite 2.0 focus on streamlining practice workflow and patient engagement with automated reminders, notifications and follow-up for remote monitoring that create an open channel of communication between doctor and patient.

St. Jude Medical Inc. announced CE Mark approval of expanded labeling for its Ellipse implantable cardioverter defibrillator (ICD), in addition to its Durata and Optisure defibrillation leads. The approvals allow existing or future patients with these technologies to undergo magnetic resonance imaging (MRI) scans without compromising device performance. The company also announced that it has received CE Mark approval for its Assurity MRI and Endurity MRI pacemaker device families. The approvals further expand St. Jude Medical’s MRI-conditional device portfolio in Europe.

Subscribe Now